WO2006113723A3 - Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease - Google Patents

Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease Download PDF

Info

Publication number
WO2006113723A3
WO2006113723A3 PCT/US2006/014575 US2006014575W WO2006113723A3 WO 2006113723 A3 WO2006113723 A3 WO 2006113723A3 US 2006014575 W US2006014575 W US 2006014575W WO 2006113723 A3 WO2006113723 A3 WO 2006113723A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
autoimmune disease
compositions
therapeutic response
Prior art date
Application number
PCT/US2006/014575
Other languages
French (fr)
Other versions
WO2006113723A2 (en
Inventor
Thomas E Carey
Thankam S Nair
Jennifer Gray Beckham
Original Assignee
Univ Michigan
Thomas E Carey
Thankam S Nair
Jennifer Gray Beckham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Thomas E Carey, Thankam S Nair, Jennifer Gray Beckham filed Critical Univ Michigan
Priority to EP06750581A priority Critical patent/EP1883420A4/en
Priority to AU2006236406A priority patent/AU2006236406B2/en
Priority to CA002605442A priority patent/CA2605442A1/en
Publication of WO2006113723A2 publication Critical patent/WO2006113723A2/en
Publication of WO2006113723A3 publication Critical patent/WO2006113723A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods of diagnosing the presence of an autoimmune disease in a patient, methods of predicting the response of an autoimmune diseased patient to therapeutic treatment, and methods of monitoring an autoimmune patient's response to therapy. In particular, these methods comprise the use of a glycoprotein from the inner-ear organ of Corti reactive with a KHRI-3 monoclonal antibody.
PCT/US2006/014575 2005-04-18 2006-04-18 Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease WO2006113723A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06750581A EP1883420A4 (en) 2005-04-18 2006-04-18 Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
AU2006236406A AU2006236406B2 (en) 2005-04-18 2006-04-18 Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
CA002605442A CA2605442A1 (en) 2005-04-18 2006-04-18 Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67245305P 2005-04-18 2005-04-18
US60/672,453 2005-04-18

Publications (2)

Publication Number Publication Date
WO2006113723A2 WO2006113723A2 (en) 2006-10-26
WO2006113723A3 true WO2006113723A3 (en) 2007-06-14

Family

ID=37115868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014575 WO2006113723A2 (en) 2005-04-18 2006-04-18 Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease

Country Status (4)

Country Link
EP (1) EP1883420A4 (en)
AU (1) AU2006236406B2 (en)
CA (1) CA2605442A1 (en)
WO (1) WO2006113723A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206564B2 (en) 2007-07-23 2012-06-26 Bayer Healthcare Llc Biosensor calibration system
US7809512B2 (en) 2007-11-11 2010-10-05 Bayer Healthcare Llc Biosensor coding system
EP2232251B1 (en) 2007-12-10 2014-03-19 Bayer HealthCare LLC An auto-calibrating test sensor and method of making the same
US8032321B2 (en) 2008-07-15 2011-10-04 Bayer Healthcare Llc Multi-layered biosensor encoding systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006788A1 (en) * 1998-12-29 2001-07-05 Thomas E. Carey Identifying the antigenic target of autoimmune sensorineural hearing loss (aisnhl) and developement of specific tests for diagnosis and management of aisnhl

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082646A1 (en) 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006788A1 (en) * 1998-12-29 2001-07-05 Thomas E. Carey Identifying the antigenic target of autoimmune sensorineural hearing loss (aisnhl) and developement of specific tests for diagnosis and management of aisnhl

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DISHER M.J. ET AL.: "Autoantibodies and Monoclonal Antibody KHRI-3 Bind to a Phylogenetically Conserved Inner-ear-supporting Cell Antigen", ANN. N.Y. ACAD. SCI., vol. 830, 29 December 1997 (1997-12-29), pages 253 - 265, XP008081840 *
NAIR T.S. ET AL.: "Identification and Characterization of Choline Transporter-Like Protein 2, an Inner Ear Glycoprotein of 68 and 72 kDa That is the Target of Antibody-Induced Hearing Loss", J. NEUROSCI., vol. 24, no. 7, 18 February 2004 (2004-02-18), pages 1772 - 1779, XP008081841 *
See also references of EP1883420A4 *

Also Published As

Publication number Publication date
CA2605442A1 (en) 2006-10-26
AU2006236406A1 (en) 2006-10-26
WO2006113723A2 (en) 2006-10-26
EP1883420A4 (en) 2008-08-27
EP1883420A2 (en) 2008-02-06
AU2006236406B2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
IL291162A (en) Isolated human rpe cells and use thereof for the treatment of degenerative diseases of the retina
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
ATE364618T1 (en) ANTIBODIES TO THE MUC18 ANTIGEN
RS20160203A1 (en) Treatment with anti-vegf antibodies
HUP0400284A2 (en) Recombinant tumor specific antibody and use thereof
TNSN07401A1 (en) ANTIBODIES AGAINST THE AMYLOID-BETA PEPTIDE AND METHODS FOR THEIR USES
EP2535355A3 (en) Antibodies against CD38 for treatment of multiple myeloma
EP2860192A3 (en) Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2003104273A3 (en) Therapeutic epitopes and uses thereof
NO20066058L (en) Antibody directed to amyloid beta-peptide, and methods for the use of the same
WO2006004910A3 (en) Improved bispecific antibodies
WO2008156713A3 (en) Anti-cd20 therapeutic compositions and methods
WO2006029879A3 (en) Anti-ox40l antibodies
AU2003295644A8 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
WO2007007173A3 (en) Human anti-madcam antibodies
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
WO2003087831A3 (en) Proteins involved in breast cancer
WO2007035857A3 (en) Treatment of b cell diseases using anti-germline antibody binding agents
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
ATE407147T1 (en) FAB FRAGMENTS HUMAN MONOCLONAL ANTIBODIES WITH NEUTRALIZING ACTIVITY AGAINST HCV E2 GLYCOPROTEIN
AU2003223172A1 (en) Use of the axl receptor for diagnosis and treatment of renal disease
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2605442

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006750581

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006236406

Country of ref document: AU